Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma
A. Basit Khan1, Collin W. English1, William C. Chen2,3,4, Prazwal Athukuri1, James C. Bayley1, Vicky L. Brandt5, Arya Shetty1, Caroline C. Hadley1, Abrar Choudhury2,3,4, Hsiang-Chih Lu5,6, Arif O. Harmanci7, Akdes S. Harmanci1, Stephen T. Magill8, David R. Raleigh2,3,4, Tiemo J. Klisch5,9, Akash J. Patel1,5,10
1Department of Neurosurgery, Baylor College of Medicine, Houston, USA
2Department of Radiation Oncology, University of California San Francisco, San Francisco, USA
3Department of Neurological Surgery, University of California, San Francisco, San Francisco, USA
4Department of Pathology, University of California, San Francisco, San Francisco, USA
5Jan and Dan Duncan Neurological Research Institute, Texas Children’s Hospital, Houston, USA
6Department of Pathology and Immunology, Baylor College of Medicine, Houston, USA
7Center for Secure Artificial Intelligence For hEalthcare (SAFE), Center for Precision Health, School of Biomedical Informatics, University of Texas Health Science Center Houston, Houston, USA
8Department of Neurological Surgery, Northwestern University, Chicago, USA
9Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, USA
10Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, USA
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Springer Science and Business Media LLC
Tập 145
501-503
Thông tin tác giả